Daewon Pharmaceutical Risk (Part 3): Domestic New Drug 'Pelubi' Patent Loss for 4th Consecutive Time, Closing Growth Plate... Corporate Crisis Revealing Absence of Strategy and Incompetence of Management 'Negative Lesson'

• 페북
• 트윗
• 카톡
• 기타